AbbVie withdraws Exviera from EU market for commercial reasons
by
Contributor since / Followers
Contributor since / Followers
2 months ago
vzphotos
- AbbVie (NYSE:ABBV) has withdrawn its hepatitis C drug Exviera from the European Union market for commercial reasons.
- The European Medicines Agency said in a statement posted on its website Tuesday that it withdrew authorization for Exviera on Sept. 25 at the request of AbbVie, which said it had decided to permanently discontinue marketing the product.
- Exviera, also known as dasabuvir, was granted market authorization with a five-year validity by the EMA in 2015 for the treatment of chronic hepatitis C. The product was later granted authorization with unlimited validity in 2019.
- The drug was sold in the U.S. as part of a combination therapy called Viekira Pak, which has since been discontinued, according to the FDA’s website.